GlassScriptPhysician profile
Caroline Mackey Mauldin
NPI 1457597080
$6,549.56
in general payments reported to CMS, 2019-2025
24 companies · $4,358 in 2025
The $4,358 reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $88.74 · 2022: $274 · 2023: $387 · 2024: $1,443 · 2025: $4,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799 · Travel and Lodging: $2,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,799.07 |
| Travel and Lodging | $2,388.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,203.11 | 2024-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Boston Scientific Corporation | $1,745.11 | 2022-2025 | General - Structural Heart, Resonate El Icd Vr, Accolade Sr |
| E.R. Squibb & Sons, L.L.C. | $422.62 | 2024-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.36 | 2021-2025 | Jardiance |
| United Therapeutics Corporation | $326.83 | 2024-2025 | Tyvaso, Tyvaso |
| Actelion Pharmaceuticals US, INC. | $292.89 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $292.77 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $184.49 | 2022-2025 | Verquvo, Winrevair |
| Pfizer INC. | $172.89 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $135.95 | 2024-2025 | Evkeeza |
| Amgen INC. | $63.82 | 2024-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $55.18 | 2021-2025 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.93 | 2021-2025 | Lifevest |
| Heartflow, INC. | $39.72 | 2025 | |
| Cvrx, INC. | $26.05 | 2025 | Barostim Neo System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.75 | 2024 | Xarelto |
| Sandoz INC. | $25.40 | 2025 | Treprostinil |
| Abiomed | $25.13 | 2025 | |
| Scpharmaceuticals INC. | $21.52 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.75 | 2025 | |
| Bridgebio Pharma, INC. | $18.94 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $17.66 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.76 | 2024 | Tryvio |
| Biosense Webster, INC. | $15.93 | 2025 | Carto 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mauldin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.